[go: up one dir, main page]

AU2001288053A1 - N-substituted benzothiophenesulfonamide derivatives - Google Patents

N-substituted benzothiophenesulfonamide derivatives

Info

Publication number
AU2001288053A1
AU2001288053A1 AU2001288053A AU8805301A AU2001288053A1 AU 2001288053 A1 AU2001288053 A1 AU 2001288053A1 AU 2001288053 A AU2001288053 A AU 2001288053A AU 8805301 A AU8805301 A AU 8805301A AU 2001288053 A1 AU2001288053 A1 AU 2001288053A1
Authority
AU
Australia
Prior art keywords
agent
substituted benzothiophenesulfonamide
substituted
chymase
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001288053A
Inventor
Takeshi Hasegawa
Shin-Ichi Kazayama
Hidekazu Masaki
Takahiro Morita
Shoji Satoh
Atsuo Takahashi
Akira Tatsui
Hideki Yamada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toa Eiyo Ltd
Original Assignee
Toa Eiyo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toa Eiyo Ltd filed Critical Toa Eiyo Ltd
Publication of AU2001288053A1 publication Critical patent/AU2001288053A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to an N-substituted benzothiophenesulfonamide derivative or a salt thereof and applications thereof. Furthermore, it provides an agent for preventing or treating cardiac or circulatory disease caused by abnormal increase of production of angiotensin II or endothelin I based on chymase activity, wherein the agent has a selective inhibitory action on chymase.
AU2001288053A 2000-09-18 2001-09-17 N-substituted benzothiophenesulfonamide derivatives Abandoned AU2001288053A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2000282046 2000-09-18
JP2000-282046 2000-09-18
JP2001-122972 2001-04-20
JP2001122972 2001-04-20
PCT/JP2001/008061 WO2002022595A1 (en) 2000-09-18 2001-09-17 N-substituted benzothiophenesulfonamide derivatives

Publications (1)

Publication Number Publication Date
AU2001288053A1 true AU2001288053A1 (en) 2002-03-26

Family

ID=26600125

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001288053A Abandoned AU2001288053A1 (en) 2000-09-18 2001-09-17 N-substituted benzothiophenesulfonamide derivatives

Country Status (8)

Country Link
EP (1) EP1325920B1 (en)
JP (1) JP3847711B2 (en)
CN (1) CN1245400C (en)
AT (1) ATE478857T1 (en)
AU (1) AU2001288053A1 (en)
CA (1) CA2422807C (en)
DE (1) DE60142914D1 (en)
WO (1) WO2002022595A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003335670A (en) * 2002-03-15 2003-11-25 Toa Eiyo Ltd Anti-adhesion agent
EP1486494B1 (en) * 2002-03-15 2010-07-14 TOA Eiyo Ltd. N-substituted benzothiophenesulfonamide derivative
EP1666067A4 (en) * 2003-08-22 2009-07-22 Teijin Pharma Ltd Drug containing chymase inhibitor as the active ingredient
CN101578265B (en) * 2007-01-10 2013-05-08 霍夫曼-拉罗奇有限公司 Sulfonamide derivatives as chymase inhibitors
US20090163586A1 (en) 2007-12-20 2009-06-25 Astrazeneca Ab Bis-(Sulfonylamino) Derivatives in Therapy 205
AU2011344146B2 (en) 2010-12-16 2017-03-16 Allergan, Inc. Sulfur derivatives as chemokine receptor modulators
EP2970239B1 (en) 2013-03-12 2018-10-10 Allergan, Inc. Sulfonamide derivatives as chemokine receptor modulators
WO2015084869A1 (en) 2013-12-02 2015-06-11 Allergan, Inc. Benzothiophene sulfonamides derivatives as chemokine receptor modulators
CN111285844B (en) * 2020-02-24 2022-08-12 河南师范大学 Biologically active benzothiophene substituted amide compounds and their synthesis methods and applications
CN119278042A (en) * 2022-04-05 2025-01-07 索克普拉健康与人文科学公司 Chymotrypsin inhibitors for selective lysis of thrombi in thrombotic or thromboembolic disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1048657A1 (en) * 1995-04-04 2000-11-02 Texas Biotechnology Corporation Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
DE69622148T2 (en) * 1995-09-28 2002-10-31 Suntory Limited, Osaka CHINAZOZINE DERIVATIVES AND THEIR USE
DZ2376A1 (en) * 1996-12-19 2002-12-28 Smithkline Beecham Plc New sulfonamide derivatives process for their preparation and pharmaceutical compositions containing them.
GB9801392D0 (en) * 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
JP2000095770A (en) * 1998-07-22 2000-04-04 Toa Eiyo Ltd N-substituted thiazolidine derivatives and pharmaceuticals containing the same
EP1114035B1 (en) * 1998-08-21 2006-05-17 Daiichi Asubio Pharma Co., Ltd. Quinazoline derivatives and pharmaceutical applications thereof
GB9818914D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
JP4491866B2 (en) * 1999-09-30 2010-06-30 三菱化学株式会社 Acylsulfonamide derivatives

Also Published As

Publication number Publication date
ATE478857T1 (en) 2010-09-15
CA2422807A1 (en) 2003-03-18
CN1458928A (en) 2003-11-26
JPWO2002022595A1 (en) 2004-01-22
EP1325920A4 (en) 2005-02-02
JP3847711B2 (en) 2006-11-22
DE60142914D1 (en) 2010-10-07
CN1245400C (en) 2006-03-15
EP1325920A1 (en) 2003-07-09
EP1325920B1 (en) 2010-08-25
CA2422807C (en) 2009-12-08
WO2002022595A1 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
WO2006028958A3 (en) Pyridyl inhibitors of hedgehog signalling
YU21702A (en) Substituted indoles for modulating nfkb activity
WO2004075865A3 (en) Selective modulation of tlr-mediated biological activity
AU2003244463A1 (en) 2,4,6-triamino-1,3,5-triazine derivative
TNSN05045A1 (en) Indole or benzimidazole derivatives for modulating ikappab kinase
EP1944059A3 (en) Device for desynchronising neuronal brain activity
PL1845095T3 (en) 1-thio-d-glucitol derivatives
WO2000077246A3 (en) A METHOD FOR IDENTIFYING A DRUG CANDIDATE HAVING AN INHIBITORY ACTION ON FVII-TF ACTIVITY, AND FVIIa/TF ACTIVITY INHIBITING COMPOUNDS
AU2001288053A1 (en) N-substituted benzothiophenesulfonamide derivatives
WO2002034201A3 (en) Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy
WO2004053069A3 (en) PROTECTION OF STEM CELLS FROM CYTOTOXIC AGENTS BY MODULATION OF β-CATENIN SIGNALING PATHWAYS
BR0017157A (en) 6-hydroxy-indazole derivatives for the treatment of glaucoma
WO2003099202A3 (en) Beta-secretase inhibitors
WO2001041709A3 (en) Methods for treating cell death diseases and inflammation
NO20032406L (en) Use of 1-phenyl-3-dimethylaminopropane compounds for the treatment of urinary incontinence
WO2004034985A3 (en) Chemical compounds
WO2005014576A8 (en) Isoquinolinone derivative, process for producing the same and use thereof
EP1591130A3 (en) Use of active solution for disinfecting and/or sterilizing a dental unit and method thereof
WO2003090674A3 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
DE60333351D1 (en) N-SUBSTITUTED BENZOTHIOPHENESULFONAMID DERIVATIVE
WO2002102369A3 (en) Agent for protection of retinal neurons
WO2003028652A3 (en) Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis
TW200509798A (en) Phenylsulfonyl carbamate derivative and plant disease control agent for agricultural or horticultural use
MXPA04004743A (en) Neurotensin active 2,3-diaryl-pyrazolidine derivatives.
WO2001011968A3 (en) Heterocyclic spiro compounds as pesticides